

**conjugated oestrogen, medroxyprogesterone
(Premique Low Dose)**

(No. 130/04)

Wyeth

Summary of Advice

08 November 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

Advice: following a full submission.

Conjugated oestrogen 0.3mg, medroxyprogesterone 1.5mg (Premique Low Dose[®]) is accepted for use within NHS Scotland as hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women with an intact uterus.

It is effective in controlling vasomotor symptoms and is associated with lower rates of breast pain and endometrial bleeding compared to other products with higher oestrogen content. It is more expensive than several other HRT therapies, but less expensive than the current market leader in Scotland.

Professor David H Lawson
Chairman